Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Stage IB-IIIA Non-small Cell Lung Carcinoma
Interventions: AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 23
States / cities: Los Angeles, California • Santa Monica, California • Santa Rosa, California + 20 more

Conditions: Chronic Rhinosinusitis
Interventions: OPN-375; Drug
Lead sponsor: Optinose US Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 46
States / cities: Gilbert, Arizona • Bakersfield, California • Folsom, California + 40 more

Conditions: Arteriovenous Graft
Interventions: SRM003, Participating Site's standard practice; Biological · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 40 more

Conditions: Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
Interventions: LYR-210, Sham procedure control, Background Therapy; Drug · Other
Lead sponsor: Lyra Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 26
States / cities: Birmingham, Alabama • Escondido, California • La Mesa, California + 21 more

Conditions: Pancreas Cancer
Interventions: GI-4000, Gemcitabine; Biological · Drug
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 18
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 14 more

Conditions: Psoriasis
Interventions: CNTO 1959; Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Miramar, Florida + 5 more

Conditions: Stroke
Interventions: Full-pressure ECP, Sham-pressure ECP; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 85 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 3
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California

Conditions: Type 2 Diabetes Mellitus
Interventions: Lixisenatide (AVE0010), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 10 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Chula Vista, California • Overland Park, Kansas • Louisville, Kentucky

Conditions: Seasonal Influenza
Interventions: mRNA-1010, Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8,411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 103
States / cities: Anniston, Alabama • Athens, Alabama • Cullman, Alabama + 85 more

Conditions: Irritable Colon
Interventions: talnetant; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 70
States / cities: Chandler, Arizona • Phoenix, Arizona • North Little Rock, Arkansas + 63 more

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo, Avonex®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Refractory Angina, Coronary Artery Disease
Interventions: XC001, Sham (No Treatment); Combination Product
Lead sponsor: XyloCor Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • Phoenix, Arizona • Atlanta, Georgia + 11 more

Conditions: Opioid Use Disorder
Interventions: Placebo, MCAM; Other · Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Major Depression
Interventions: Psilocybin (Usona Institute), Propofol, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 25 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Ischemic Stroke
Interventions: Elezanumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years to 90 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 22
States / cities: Phoenix, Arizona • Long Beach, California • Washington D.C., District of Columbia + 18 more

Conditions: Chronic Sinusitis
Interventions: PROPEL Mini Sinus Implant., Sinus Surgery alone, Propel Nova Sinus Implant; Device · Procedure
Lead sponsor: Intersect ENT; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Sacramento, California • Torrance, California • Norwalk, Connecticut + 7 more

Conditions: Primary Sclerosing Cholangitis
Interventions: PLN-74809, Placebo; Drug
Lead sponsor: Pliant Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 21
States / cities: Pasadena, California • Redwood City, California • Sacramento, California + 17 more

Conditions: Major Depressive Disorder
Interventions: CP-601,927, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 58
States / cities: Little Rock, Arkansas • Beverly Hills, California • Garden Grove, California + 44 more

Conditions: Plasmodium Falciparum Infection
Interventions: Placebo, Ad35.CS.01 Circumsporozoite Malaria Vaccine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 2
States / cities: Stanford, California • Nashville, Tennessee

Conditions: Hypotension
Interventions: Nitroprusside; Drug
Lead sponsor: The Emmes Company, LLC; Industry
Eligibility: Up to 17 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: IPF
Interventions: HNC1058 Capsules; Drug
Lead sponsor: Guangzhou Henovcom Bioscience Co. Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Amyotrophic Lateral Sclerosis
Interventions: NP001, Placebo; Drug
Lead sponsor: Neuraltus Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more

Conditions: Focal Seizure, Epilepsy, Focal Epilepsy
Interventions: RAP-219, Placebo; Drug · Other
Lead sponsor: Rapport Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Huntsville, Alabama • Bentonville, Arkansas • Colorado Springs, Colorado + 9 more

Conditions: Obesity, Non-Alcoholic SteatoHepatitis (NASH)
Interventions: Survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 33
States / cities: Fountain Valley, California • Gardena, California • Long Beach, California + 29 more

Search by objective public record fields.

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps

An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Placement of an Arteriovenous Graft to Facilitate Hemodialysis Access

Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults

Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

Safety Study of External Counterpulsation as a Treatment for Acute Ischemic Stroke

Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.

Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants

Study of Psilocybin Under Anesthesia Controlled by EEG

A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression

Adenovirus Vaccine for Malaria

Dose-response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)